Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy

Table 1 Clinical-pathological features n (%)

	Cases	sTIL ≥ 50%	P value	pCR	P value	Overall Survival at 5 yr(OS = 50.1%)	P value	Progression free survival at 5 yr(DFS = 57.8%)	P value
	435	181		48
Age (yr), median (range)	49 (24-84)	49 (24-84)	0.923	47 (28-80)	0.472		0.512		0.833
< 50	231 (53.1)	96 (35.2)		28 (12.1)		48.8%		59.7%
≥ 50	204 (46.9)	85 (36.7)		20 (9.8)		51.7%		55.9%
Histological subtypes			0.928		0.234		0.512		0.497
Ductal	406 (93.3)	169 (43.6)		43 (10.6)		49.0%		57.5%
Lobular	21 (4.8)	7 (36.8)		2 (9.5)		61.0%		55.2%
Others	8 (1.8)	5 (62.5)		3 (37.5)		-		-
Histological grade			< 0.001		0.170		0.001		0.006
G1-G2	200 (46.0)	59 (32.6)		17 (8.5)		57.1%		64.6%
G3	227 (52.2)	119 (65.7)		29 (12.8)		42.8%		52.2%
NR	8 (1.8)	3 (1.7)		2 (25)		83.3%		45.7%
ER			< 0.001		0.098		< 0.001		0.000
No	162 (37.2)	89 (57.8)		23 (14.2)		36.1%		47.1%
Yes	273 (62.8)	92 (35.2)		25 (9.2)		58.2%		64.3%
PgR			0.003		0.246		< 0.001		0.000
No	213 (49)	104 (51.0)		27 (12.7)		41.0%		50.0%
Yes	222 (51)	77 (36.5)		21 (9.5)		58.4%		64.8%
HER2			0.002		0.135		0.334		0.135
No	294 (67.6)	106 (38.3)		28 (9.5)		53.7%		60.4%
Yes	141 (32.4)	75 (54.3)		20 (14.2)		40.8%		52.3%
Molecular subtypes			< 0.001		0.233		< 0.001		< 0.001
Luminal A	107 (24.6)	30 (29.7)		13 (12)		72.0%		76.1%
Luminal B	165 (37.9)	61 (38.4)		12 (7)		50.6%		57.7%
HER2-enriched	77 (17.7)	50 (66.7)		10 (13)		41.5%		54.9%
Triple-Negative	86 (19.8)	40 (50.0)		13 (15)		32.5%		40.3%
Tumor size (cm)			0.183		0.019		0.490		0.250
Median (range)	6.5 (1-24)	6.5 (1-16)		6.0 (2-15)
cT
cT1-cT2	36 (8.3)	19 (54.3)		8 (22.2)		55.0%		69.2%
cT3-cT4	399 (91.7)	162 (42.6)		40 (10)		49.6%		56.8%
cN			0.084		0.743		0.007		0.001
cN0	83 (19.1)	28 (35.0)		10 (12)		65.8%		77.0%
cN1-cN2-cN3	352 (80.9)	153 (45.7)		38 (10.8)		47.2%		54.2%
Clinical stage			0.192		0.088		0.155		0.004
II	72 (16.6)	26 (36.6)		12 (16.7)		62.1%		74.3%
III	363 (83.4)	155 (45.1)		36 (9.9)		48.1%		55.4%
sTIL%					0.002		0.598		0.747
Median (range)	40 (2-95)	70 (60-95)		65 (5-95)
< 50%	266 (61.1)	0 (0)		20 (7.5)		49.6%		55.7%
≥ 50%	149 (34.3)	181 (100)		26 (17.4)		53.9%		63.1%
Missing data	20 (4.6)	20 (0)		2 (10)		-		-
TLCS (d)			0.411		0.633		0.317		0.156
Median (range)	63 (5-982)	58 (8-982)		65 (8-281)
Shorter than median	207 (47.6)	91 (45.5)		22 (10.6)		48.5%		55.0%
Longer than median	211 (48.5)	82 (41.4)		26 (12.3)		56.7%		61.2%
Missing data	17 (3.9)	8 (47.1)		0 (0)		17.6%		46.3%
pCR			0.029				0.002		0.002
No	387 (89)	154 (41.7)		0 (0)		47.4%		55.1%
Yes	48 (11)	27 (58.7)		48 (100)		85.1%		84.9%
Relapse			0.895		< 0.001		< 0.001
No	284 (65.3)	118 (43.4)		42 (14.8)		81.6%		-
Yes	151 (34.7)	63 (44.1)		6 (4)		8.58%		-

TIL: Tumor-infiltrating lymphocytes; pCR: Pathological complete response; OS: Overall survival; DFS: Disease free survival; PgR: Progesterone; TLCS: Time-From-Last-Chemotherapy-To-Surgery.